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Purpose: Lung volume reduction using one-way endobronchial valves is a bronchoscopic
treatment for patients with severe emphysema without collateral ventilation between the treat-
ment target lobe and the ipsilateral lobe(s). CT-scan fissure analysis is often used as a surrogate to
predict the absence of collateral ventilation. We aimed to evaluate the predictive value of the
fissure completeness score (FCS) compared to the functional Chartis measurement of collateral
ventilation and to provide cut-off values of the FCS in patient selection.
Patients and Methods: Multicenter study in patients eligible for treatment with one-way
valves. The FCS was calculated by quantitative CT analysis (Thirona, the Netherlands) and
compared to status of interlobar collateral ventilation measured with Chartis system
(PulmonX, USA). Thresholds were calculated for the predictive values of the presence of
collateral ventilation.
Results: An FCS >95% of the left major fissure had a positive predictive value (PPV) of
91%, with 1 in 11 fissures demonstrating collateral ventilation with Chartis measurement,
whereas an FCS of ≤80% had a negative predictive value (NPV) of 100% for the presence of
collateral ventilation. For the right major fissure, the NPV was 100% for an FCS ≤90%, but
69.7% for the right upper lobe fissure.
Conclusion: Quantitative CT analysis is recommended in all patients evaluated for endo-
bronchial valves. Patients with incomplete fissures (left major fissure: FCS <80%; right
major fissure: <90%) can be excluded from Chartis measurement and endobronchial valve
treatment. In patients with more complete fissures, the FCS is not specific enough for
endobronchial valve treatment decisions. In this case, additional Chartis measurements are
always recommended in the right lung. For the left lung, Chartis assessments may be omitted
if the FCS is >95%.
Keywords: COPD, lung volume reduction, fissure, collateral ventilation, CT scan
Introduction
Bronchoscopic lung volume reduction with endobronchial valves (EBV) is an addi-
tional treatment option for patients with severe emphysema and hyperinflation. The
purpose of this treatment is to achieve volume reduction of the most diseased lobe.
During this treatment, one-way endobronchial valves are placed in all (sub-)segments
of the most diseased lobe to achieve lobar occlusion. This treatment has been proven
effective in multiple studies, and provides clinically meaningful benefits in lung
function, dyspnea, quality of life and exercise tolerance in a selected group of patients
with chronic obstructive pulmonary disease (COPD).1–8
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However, treatment is only effective in carefully
selected patients. The most important factor for an effec-
tive treatment is the absence of interlobar collateral venti-
lation. If collateral ventilation is present between the target
lobe and adjacent ipsilateral lobe(s), the placement of one-
way valves will not achieve the desired atelectasis, result-
ing in no clinically meaningful benefit.9–13
Collateral ventilation can be functionally measured
using the Chartis system® (PulmonX Inc., Redwood City,
CA, USA).12,14,15 With this method, a catheter with
a balloon component at the end is inflated in the entrance
of the airways of the target treatment lobe. The Chartis
console then measures the expiratory airflow from this
lobe. If airflow persists after balloon occlusion, this indi-
cates that there is collateral ventilation. However, if the
flow decreases over time and gradually stops, this indi-
cates the absence of collateral ventilation and these
patients are suitable for treatment with valves.
Although Chartis measurement proved to be a valuable
and reliable tool, it is a time-consuming bronchoscopic
procedure if used in all patients with severe hyperinflation
regardless if they will receive valves, as many have col-
lateral ventilation. If this measurement could be avoided in
patients with certain presence (or absence) of collateral
ventilation, this would save burden, time and costs.
An indirect and non-invasive method for assessment of
collateral ventilation is the fissure completeness score
(FCS) calculated on high-resolution computed tomography
(HRCT) using quantitative CT analysis (QCT). A high
score indicates that an interlobar fissure is (nearly) com-
plete and that the likelihood of having collateral ventila-
tion is small, though not absent.15 Until recently, a fissure
was defined as complete on HRCT scan if the fissure
integrity was more than 90 percent.1–3,14,16-18 This value
is relatively arbitrary and studies found rather variable
relations between the FCS and treatment outcome.
A recent study supports the use of combining the fissure
completeness scores and Chartis measurements and
advised a Chartis measurement in patients with FCS
between 80% and 95%, exclude patients with FCS<80%
and treat patients with FCS>95%.15 There is a need for
confirmation regarding these cut-offs, given the impor-
tance of accurately selecting the responder patients.12,13
Although Chartis measurement is clinical practice in many
clinics, there are recent studies that advocate the use of the
fissure cut-off score of 90% only.19,20 However, more
accurate selection of responder patients prevents unneces-
sary procedures, non-beneficial treatments and extra costs
in patients with collateral ventilation. Therefore, we per-
formed a study to correlate the FCS to the Chartis assess-
ment. In this study, we investigated in which patients
additional Chartis assessments are recommended or can
be avoided with detailed quantitative assessment of the
FCS on HRCT. Additionally, we evaluated costs involved
in adding Chartis assessment.
Patients and Methods
Study Design
This is a retrospective multicenter study comparing out-
comes of the quantitative assessment of the FCS on
HRCT with Chartis measurements in a routine clinical
care setting in the University Medical Center Groningen,
the Netherlands and in the Charité University Clinic,
Berlin, Germany. The study was conducted in accor-
dance with the declaration of Helsinki, and all patients
provided written informed consent regarding their treat-
ment and use of their data for future scientific purposes,
which was approved by the medical ethics committee of
the University Medical Center Groningen
(METc2016.483) and of the Charité University Clinic
(EA2/149/17). All data was anonymized and treated
with confidentiality according to GCP guidelines.
Patients were selected for treatment based on their
primary assessment and work-up including a pulmonary
function test, high-resolution CT scan (maximum 1 mm
slice thickness) and QCT analysis with a target lobe for
treatment with (near) complete fissures between the target
lobe and the ipsilateral lobe. During the valve procedure,
Chartis is performed and if there is no collateral ventila-
tion, valves are placed. All patients who were scheduled
for a valve treatment procedure and who have signed an
informed consent form were included in this study. The
Chartis measurement was performed for the target lobe
fissure first, and preferably all other fissures to gather
information regarding the presence or absence of collateral
ventilation over the other fissures.
Assessment of FCS on HRCT
QCT analysis was performed on all baseline scans using
Thirona LungQ version 1.0.0 (Thirona BV, Nijmegen, the
Netherlands) to assess fissure completeness and lobar tissue
destruction at baseline for each subject. The methods for QCT
analysis and calculation of the FCS have been described
previously.15 In each chest CT scan, the lungs, fissures and
lobes were automatically segmented and afterwards visually
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checked and edited by trained medical analysts. Based on
these results, FCSwas computed for each lobe. This is defined
as the percentage of the lobar boundaries defined by a fissure.
Chartis Measurement
Collateral ventilation was assessed as previously
described using the Chartis system.21 The measurements
were performed under either spontaneous breathing with
conscious sedation (Berlin) or under general anesthesia
(Groningen) using a flexible therapeutic bronchoscope.
The Chartis balloon was placed in the entrance of the
upper lobe and/or the lower lobe from the right lung and
the left lung.
In the right lung, the major fissure can be measured in
the lower lobe or in the upper lobe while blocking the
middle lobe with a Fogarty balloon or Watanabe spigot.
The right upper lobe fissure consists of the minor fissure
and a part of the major fissure (Figure 1) and is measured
with Chartis in the right upper lobe. In the left lung, the
major fissure can be measured in the lower lobe or in the
upper lobe. Preferably, the target lobe was chosen to be
measured first. Chartis results were defined as presence of
collateral ventilation (CVpos), absence of collateral venti-
lation (CVneg), or “not conclusive”, if the status of collat-
eral ventilation could not be concluded. These assessments
include the “low flow” or “no flow phenotype” (also
known as “collapse phenotype”) and the “low plateau
phenotype” as recently reported.22,23
Statistical Analyses
Patientswere included in the analysis if they underwentChartis
assessments and had an evaluable baseline HRCT. The FCS
was evaluated for its ability to predict the Chartis outcome, for
which a receiver operating characteristics (ROC) curve was
created. Sensitivity, specificity, positive and negative predic-
tive values were calculated for each FCS. We aimed to calcu-
late two FCS thresholds for both major fissures and the right
upper lobe fissure. The first lower threshold of FCS was set to
minimize the number of false negatives (incomplete FCSwith-
out presence of collateral ventilation). The second higher
threshold of FCS was defined to minimize the number of
false positives (complete FCS but presence of collateral venti-
lation). This will result in three groups for each fissure: 1)
incomplete fissure (less than lower FCS threshold); 2) com-
plete fissure (more than higher FCS threshold); 3) partially
complete fissure (FCS between two thresholds). IBM SPSS




In total, 240 patients with COPD and eligible for EBV treat-
ment were included, and the FCS of the right major fissure,
right upper lobe fissure and left major fissure (Figure 1) were
measured with QCT analysis. In these patients, 429 fissures
were categorized as “presence of collateral ventilation between
Figure 1 Measurement of collateral flow with Chartis. (A) and (B) Collateral flow over the left major fissure (red) is measured by a balloon occluding the entrance of the
left lower lobe (A) or the left upper lobe (B). (C) Collateral flow over the right upper lobe fissure is measured in the right upper lobe. This fissure consists of the minor
fissure and a part of the right major fissure (red). (D) Collateral flow over the right major fissure (red) is measured by a balloon occluding the entrance of the right lower
lobe. If this is unsuccessful, (E) collateral flow can be measured in the right upper lobe while the middle lobe is also occluded with a Fogarty balloon or a Watanabe spigot
(green).
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EBV target lobe and ipsilateral lobe” (CVpos) or “absence of
collateral ventilation between EBV target lobe and ipsilateral
lobe” (CVneg) with Chartis assessments. The baseline charac-
teristics of the included subjects are presented in Table 1.
Assessment of the Fissure Completeness
Score on HRCT and Chartis Assessment
The median FCS of the right major fissure was 97.1% (range
60.2–100%), right upper lobe fissure 85.3% (range 23.4–-
100%) left major fissure 99.9% (range 49.7–100%). Chartis
measurement was performed under conscious sedation in
113 patients and under general anesthesia in 127 patients.
Chartis assessment of the right major fissure was performed
in 106 patients (44%). Of these, 41 patients (39%) had
presence of collateral ventilation and 65 patients (61%) had
absence of collateral ventilation. The right upper lobe fissure
was conclusively measured in 115 patients: 65 patients
(57%) were CVpos and 50 patients (43%) were CVneg.
Chartis assessment over the left major fissure was success-
fully performed in 208 patients of whom 40 were CVpos
(19%) and 168 were CVneg (81%).
Fissure Completeness Score versus
Chartis Outcome
The median FCS was significantly higher in patients with-
out collateral ventilation (p<0.001) in all groups, see Table
2. Figure 2 shows the percentage of patients with or with-
out collateral ventilation per fissure divided into subgroups
of FCS. The predictive values per fissure and FCS are
shown in Table 3.
Right major fissure: The area under the curve (AUC) of the
ROC-curve is 0.789 (Figure 3A). Lower cut off: FCS of
≤90% has a negative predictive value of 100%. Upper Cut
off: patients with FCS >95% have a positive predictive value
of 73.7%, compared to 85.7% in patients with a fissure
integrity of 100%.
Right Upper Lobe Fissure: The AUC of the ROC-
curve is 0.767 (Figure 3B). Lower Cut off: of the 24
patients with FCS ≤75%, 3 were CV negative. The FCS
of these patients were 75.0%, 55.6% and 25.1%. Upper
Cut off: the positive predictive value of FCS >95% is
73.2%, and 81.3% with an FCS of 100%. Even with an
FCS of 100%, 18.8% of the patients showed evidence of
collateral ventilation, compared to 26.8% with an FCS
of >95%.
Left Major Fissure: The AUC of the ROC-curve is
0.829 (Figure 3C). Lower Cut off: an FCS of ≤80% has
a negative predictive value of 100%. Upper Cut off:
patients with FCS >95% have a positive predictive
value of 91.1%, compared to 92.8% with a fissure
integrity of 100%.
Costs
To analyze the cost effectiveness of treating patients based on
FCS alone or in combination with additional Chartis mea-
surements, a costs-analysis was performed based on pub-
lished data by Hartman et al, assuming 100 hypothetical
patients.24 Based on the predictive values of the FCS, com-
bining FCS and Chartis assessments before endobronchial
valve treatment is always cost-effective in both fissures in the
right lung (Figure 4). However, in regard to the left major
fissure, it is cost-effective to treat without an additional
Chartis measurement using an FCS >95%.
Discussion
Patients with severe emphysema can be successfully trea-
ted with endobronchial valves.1,2,6-8,18 Careful patient
selection is crucial, and the absence of collateral ventila-
tion is one of the most important predictive factors for
Table 1 Baseline Characteristics
Patients (N) 240
Female (N) 142 (59%)
Age (years) 66 ± 8
BMI (kg/m2) 24 ± 4
Pack years 45 ± 24
Lung function FEV1 (%pred) 27 ± 7
RV (%pred) 232 ± 51
TLC (%pred) 131 ± 18
DLCO (%pred) 30 ± 12
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume; RV, resi-
dual volume; TLC, total lung capacity; DLCO, diffusing capacity of the lung for
carbon monoxide.
Table 2 Fissure Completeness Score Compared to Chartis
Measurement
FCS CV Positive CV Negative
Median Range Median Range
Right major fissure 94.8 60.2–100 98.9 91.1–100
Right upper lobe fissure 83.4 23.4–76.6 97.2 25.1–100
Left major fissure 91.4 49.7–100 100 82.9–100
Abbreviations: FCS, fissure completeness score; CV positive, presence of collat-
eral ventilation; CV negative, absence of collateral ventilation.
Klooster et al Dovepress
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a successful treatment. Valves placed in patients who turn
out to have collateral ventilation are a burden to patients,
treating teams and healthcare costs. We show in which
patients additional assessments of collateral ventilation can
lead to improved outcomes and cost savings.
The importance of collateral ventilation and the role of
the FCS was acknowledged soon after the first treatments
with endobronchial valves.18 QCT analysis provides an
easy and non-invasive tool to assess the FCS as
a surrogate for collateral ventilation. The FCS is predictive
for the presence or absence or collateral ventilation, which
is frequently used to preselect patients for treatment.
However, although a correlation of FCS with the like-
lihood of collateral ventilation is evident, the degree of
the correlation remains subject to discussion. Various stu-
dies used a cut-off value of 90% to define a fissure as
complete.3,14,16,18,20 However, as our study shows, even
with a fissure integrity of over 90%, a significant number
of patients still have collateral ventilation and will not
benefit from endobronchial valve treatment.
Two recently published randomized controlled trials trea-
ted patients based onFCS>90%alone, theEMPROVEand the
REACH trial.19,20 They showed an FEV1 improvement of
>15% in 37.2% and 41% of the patients, an RV reduction of
402 and 420 mL and a target lobe volume reduction of
>350 mL reduction in 74.5 and 66.1%, respectively.
However, the mean FCS in the REACH trial was 97.8% and
themean FCS of the EMPROVE trial is not known. The effect
in a subgroup of patients with fissures between 90% and 95%
or how much of these patients are treated are not given. The
LIBERATE and the TRANSFORM trial treated patients based
on the presence of collateral ventilation measured by Chartis
and showed an improvement of FEV1 >15% in 47.7% and
>12% in 56.3%, the TLV-reduction >350mLwas 89.9% at 12
months and 89.9 at 6weeks, respectively.5,8 Furthermore, there
is a difference in the occurrence of pneumothorax between
these methods. The trials that treated patients only after the
exclusion of collateral ventilation based on Chartis measure-
ment reported a pneumothorax incidence between 26% and
29%,5,6,8 which is significantly higher than the rate of 4–14%
reported in studies using only the 90% FCS cutoff.19,20,25
A higher pneumothorax incidencemight indicate a larger treat-
ment effect. Therefore, the effect appears to be more pro-
nounced in studies using the Chartis measurement as the
ultimate patient selection tool.
An earlier study suggested that the combination of Chartis
and fissure analysis provides a useful workflow in patients
eligible for endobronchial lung volume reduction by division
in three groups.15 Patients with incomplete fissures (FCS
<80%) can be excluded from further valve treatment evalua-
tion. Partially complete fissures (FCS between 80% and 95%)
should be assessed with Chartis prior to treatment and high
FCS (>95%) can be treated without additional Chartis
Figure 2 Distribution of collateral ventilation. Percentage of patients with CVneg or
CVpos compared to the fissure completeness score of the right major fissure, the
right upper lobe fissure and the left major fissure. Number of patients: Right Major
Fissure: 106; Right Upper Lobe Fissure: 115; Left Major Fissure: 208.
Abbreviations: CVpos, presence of collateral ventilation; CVneg, absence of col-
lateral ventilation.
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measurement. However, the outlined algorithm does not take
into account any possible differences between the fissures. Our
current study indicates that the leftmajorfissure, being the only
boundary between the two lobes, is more predictive than the
FCS of the right pulmonary fissures for the presence of collat-
eral ventilation. Only a very high FCS of at least 95%, and this
only for the left major fissure, should actually be used to
abstain from Chartis measurement. An individual example of
Table 3 Predictive Values per Fissure Completeness Score
Right Major Fissure (N=106)
FCS CVneg CVpos Sens Spec PPV NPV Number of Chartis Needed*
>80 64.4% 35.6% 12.2 96.0 64.4 100.0 2.8
>83 65.0% 35.0% 14.6 100.0 65.0 100.0 2.9
>85 67.0% 33.0% 22.0 100.0 67.0 100.0 3.0
>90 69.9% 30.1% 31.7 100.0 69.9 100.0 3.3
>93 74.7% 25.3% 48.8 95.4 74.7 87.0 4.0
>95 73.7% 26.3% 51.2 86.2 73.7 70.0 3.8
>96 76.5% 23.5% 61.0 80.0 76.5 65.8 4.3
>97 77.8% 22.2% 65.9 75.4 77.8 62.8 4.5
>98 81.6% 18.4% 78.0 61.5 81.6 56.1 5.4
>99 80.0% 20.0% 82.9 43.1 80.0 47.9 5.0
100 85.7% 14.3% 92.7 27.7 85.7 44.7 7.0
Right Upper Lobe Fissure (N=115)
FCS CVneg CVpos Sens Spec PPV NPV Number of Chartis Needed*
>75 40.9% 59.1% 32.3 94.0 51.6 87.5 1.7
>80 56.0% 44.0% 43.1 96.1 56.0 90.3 2.3
>83 54.7% 45.3% 47.7 82.0 54.7 77.5 2.2
>85 58.2% 41.8% 56.9 78.0 58.2 77.1 2.4
>90 66.0% 34.0% 73.8 66.0 66.0 73.8 2.9
>93 69.6% 30.4% 78.5 64.0 69.6 73.9 3.3
>95 73.2% 26.8% 83.1 60.0 73.2 73.0 3.7
>96 73.0% 27.0% 84.6 54.0 73.0 70.5 3.7
>97 71.4% 28.6% 84.6 50.0 71.4 68.8 3.5
>98 73.3% 26.7% 87.7 44.0 73.3 67.1 3.8
>99 80.8% 19.2% 92.3 42.0 80.8 67.4 5.2
100 81.3% 18.8% 95.4 26.0 81.3 62.6 5.3
Left Major Fissure (N=208)
FCS CVneg CVpos Sens Spec PPV NPV Number of Chartis Needed*
>80 85.3% 14.7% 27.5 98.8 85.3 100.0 6.8
>83 86.1% 13.9% 32.5 99.4 86.1 92.9 7.2
>85 86.3% 13.7% 35.0 97.6 86.3 77.8 7.3
>90 88.2% 11.8% 45.0 97.6 88.2 81.8 8.5
>93 89.9% 10.1% 55.0 95.2 89.9 73.3 9.9
>95 91.1% 8.9% 62.5 91.7 91.1 64.1 11.3
>96 92.7% 7.3% 70.0 90.5 92.7 63.6 13.7
>97 93.5% 6.5% 75.0 85.7 93.5 55.6 15.4
>98 93.7% 6.3% 77.5 79.8 93.7 47.7 15.9
>99 93.8% 6.2% 80.0 72.0 93.8 40.5 16.1
100 92.8% 7.2% 82.5 53.6 92.8 29.7 13.9
Notes: Statistics per fissure and fissure completeness score regarding the sensitivity, specificity, positive and negative predictive value. Number of Chartis needed*: Number
of Chartis measurements needed to identify one additional patient with collateral ventilation while applying this FCS.
Abbreviations: FCS, fissure completeness score; CVpos, presence of collateral ventilation; CVneg, absence of collateral ventilation; sens, sensitivity; spec, specificity; PPV,
positive predictive value; NPV, negative predictive value.
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a patient with a near-complete right major fissure and still
collateral ventilation is provided in Figure 5.
Our data indicates that for the left major fissure, patients
with FCS <80% should be excluded from endobronchial valve
treatment in the left lung without the need for further Chartis
assessment. Regarding the right major fissure, all patients with
an FCS below 90% had evidence of collateral ventilation and
do not benefit from additional Chartis measurement. This is
particularly interesting in the context that the FCS cut off of
90% suggested in previous clinical studies is too low to define
a fissure as complete.2,14,18-20
The right upper lobe fissure is anatomically different
from both major fissures, consisting of the minor and a part
of the right major fissure. Our data shows that a few numbers
of patients had no collateral ventilation with Chartis assess-
ment even with an FCS of the right upper lobe below 75%. It
is not known why this difference exists between the right
lung and the left lung. Possibly, the mechanism of collateral
ventilation is slightly different. One possible explanation is
the way the major and minor fissures are shaped. There is
a lot of variation in the way the fissures are formed, as is
indicated by two examples in Figure 6. Even with a near-
complete fissure on quantitative CTscan, the way the fissures
are merged may lead to a small gap and collateral ventilation.
The reason why there is no collateral ventilation, even
with incomplete fissure may be due to the extent of disease
of the pulmonary tissue. In emphysematous lungs, the resis-
tance of the airways is much higher compared to healthy
lungs. On the other hand, the resistance of the collateral
channels is much lower in emphysematous lungs.
Therefore, in emphysematous lungs, there is much more
collateral flow over the collateral channels compared to
healthy lungs.26 The mechanism of collateral ventilation
between lobes through parenchymal bridges is unknown,
but it is assumed that the mechanism might be the same as
intralobar collateral ventilation.9,27,28 Therefore, it can be
hypothesized that in relatively healthy lung tissue there is
no presence of collateral ventilation due to the high resis-
tance of the collateral channels, but only in emphysematous
lobes, with a low resistance of the collateral challenge.
Thus, if collateral ventilation is measured in a relatively
healthy right upper lobe, there may be no collateral ventila-
tion due to the high resistance, even if the fissure is incom-
plete. This may also be the case in an emphysematous right
upper lobe, but healthier middle and lower lobe. More
research is needed to clarify this issue.
Figure 3 Receiver Operating Characteristic Curves. (A) Right major fissure: The area under the curve (AUC) is 0.789. (B) Right upper lobe fissure: The AUC is 0.767. (C)
Left major fissure: The AUC is 0.829.
Figure 4 Cost analysis. Hypothetical graph of the costs of 100 patients for treatment
with endobronchial valves. Costs: Endobronchial valve treatment in all patients without
Chartis assessment: € 12.447 per patient. Chartis measurement followed by treatment
with valves: € 13.197 per patient; Chartis assessment not followed by treatment: €
3670.61 per patient.24 The “treat all” group indicates the costs of treating all 100
patients with a high FCS (indicated on x-axis) and without Chartis assessment. In the
other groups (RULF, LMF and RMF), Chartis measurement is performed in all patients,
but patients are only treated with endobronchial valves if they are CVneg.
Abbreviations: RULF, Right Upper Lobe Fissure; LMF, Left Major Fissure; RMF,
Right Major Fissure.
Dovepress Klooster et al
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Nevertheless, for the right upper lobe, this means that
a lower threshold for the FCS should be employed to guide
treatment decisions regarding the right upper lobe, and
additional Chartis assessments are strongly encouraged if
the right upper lobe is a good target but the fissures are
incomplete.
For the upper limit threshold for the FCS, the necessity
of an additional Chartis measurement can be based on two
major considerations.
Cost Aspect
If patients with an FCS above a certain threshold would all be
treated with endobronchial valves without performing an addi-
tional Chartis assessment, costs for the Chartis catheter would
be saved. On the other hand, without Chartis measurement,
Figure 5 Example of a patient with heterogeneous severe emphysema, with a nearly complete right major fissure but with evidence of collateral ventilation in Chartis
assessment. (A and B) Severe emphysema is located mainly in the right upper lobe. The fissure appears to be complete in A, but shows a small defect in figure
B (arrow). (C) Results of the quantitative CT analysis of the right lung. Fissure completeness score of the right major fissure suggested a nearly complete fissure
(98.8%) for the right lower lobe. The right upper lobe fissure (76.9%) and right middle lobe fissure (77.8%) were quantified as less complete. (D) Visual
representation of the fissure. The right side represents a complete left major fissure (green) without any gaps. The left side represents a nearly complete right
major fissure (green) with minor gaps (red). (E) Chartis measurement of the right major fissure in the right lower lobe. It shows a persistent flow over time, as
evidence of collateral ventilation through the major fissure.
Abbreviations: RUL, Right Upper Lobe; RML, Right Middle Lobe; RLL, Right Lower Lobe.
Figure 6 Formation of the right fissures. (A) The minor fissure (green dots)
merges with a part of the right major fissure (red arrows). There is a gap
between the superior and inferior part of the right major fissure, but
the minor fissure is continuous with the superior part of the major fissure.
(B) The major fissure is complete, the minor fissure merges with the major
fissure.
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a high number of patients would receive valves without effect,
which is costly. Moreover, these valves may have to be
removed, resulting in further bronchoscopies and hospital
admissions. For more clarification, we performed a costs-
analysis to compare the selection for treatment based on the
fissure score alone to the combination of the FCS with Chartis
measurement. For the right lung, all FCS should be combined
with a Chartis measurement. For the left lung, patients can be
treated based on an FCS >95%, without Chartis assessment.
Basis for the calculations is costs and reimbursements in the
Netherlands and will yield different thresholds in other
countries.
Number of Chartis Needed
This represents the number of patients presumed to have
complete fissures according to FCS, but have evidence of
collateral ventilation in Chartis measurement. With the data
from Table 3, it is shown in howmany patients a Chartis needs
to be performed to prevent one patient from inadvertently
receiving valves while there is collateral ventilation. This
consequence should be discussed with patients. We believe
Chartis should always be performed in the right lung and for
the left lung an FCS > 95% could be acceptable (Figure 7).
A low FCS indicates a high likelihood of presence of
collateral ventilation. Potential target lobes with incomplete
fissures are rarely chosen for endobronchial valve treatment.
Therefore, outcome data in this setting are lacking. It has
already been shown that treatment of patients with presence
of collateral ventilation is not effective.18,21We definedChartis
measurement as the most reliable predictor of success in endo-
bronchial valve treatment since it functionally measures the
collateral ventilation. Future studies may evaluate whether
patients with a high FCS and low collateral flow may still
benefit from treatment after treatment with endobronchial
valves.
Conclusion
In conclusion, if a patient appears to be eligible for endobron-
chial valve treatment based on their CTscan, lung function and
other characteristics, quantitative CT analysis for the FCS is
a useful but imperfect tool to further select patients for endo-
bronchial valve treatment. We strongly encourage the use of
both the FCS and Chartis measurement as patient selection
tools, and not the FCS alone, as is suggested in some recent
literature.
Patients with incomplete fissures (FCS<80% for left major
fissure and FCS <90% for right major fissure) can be excluded
from endobronchial valve treatment and no Chartis measure-
ment is needed.
In patients with (more) complete fissures, Chartis is always
recommended in the right lung. For the left lung, Chartis
assessments can optionally be omitted if the FCS is >95%.
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